Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy.
Axons
chronic inflammation
magnetic resonance imaging
multiple sclerosis
neurodegeneration
Journal
Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
24
10
2019
revised:
04
02
2020
accepted:
18
02
2020
entrez:
18
5
2020
pubmed:
18
5
2020
medline:
5
2
2021
Statut:
ppublish
Résumé
Clinicians involved with different aspects of the care of persons with multiple sclerosis (MS) and scientists with expertise on clinical and imaging techniques convened in Dallas, TX, USA on February 27, 2019 at a North American Imaging in Multiple Sclerosis Cooperative workshop meeting. The aim of the workshop was to discuss cardinal pathobiological mechanisms implicated in the progression of MS and novel imaging techniques, beyond brain atrophy, to unravel these pathologies. Indeed, although brain volume assessment demonstrates changes linked to disease progression, identifying the biological mechanisms leading up to that volume loss are key for understanding disease mechanisms. To this end, the workshop focused on the application of advanced magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging techniques to assess and measure disease progression in both the brain and the spinal cord. Clinical translation of quantitative MRI was recognized as of vital importance, although the need to maintain a relatively short acquisition time mandated by most radiology departments remains the major obstacle toward this effort. Regarding PET, the panel agreed upon its utility to identify ongoing pathological processes. However, due to costs, required expertise, and the use of ionizing radiation, PET was not considered to be a viable option for ongoing care of persons with MS. Collaborative efforts fostering robust study designs and imaging technique standardization across scanners and centers are needed to unravel disease mechanisms leading to progression and discovering medications halting neurodegeneration and/or promoting repair.
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-266Subventions
Organisme : NIH HHS
ID : R01 NS082347
Pays : United States
Organisme : NIH HHS
ID : R01 NS080816
Pays : United States
Organisme : National Multiple Sclerosis Society
ID : CA TA 3062-A-3
Pays : International
Organisme : NIH HHS
ID : R01 MH112847
Pays : United States
Organisme : NIH HHS
ID : RO1 NS109114-01
Pays : United States
Organisme : NIH HHS
ID : K01 EB023312
Pays : United States
Organisme : CIHR
ID : FDN‐143263
Pays : Canada
Organisme : NIH HHS
ID : P41 EB015894
Pays : United States
Organisme : NINDS NIH HHS
ID : P30 NS076408
Pays : United States
Organisme : NIH HHS
ID : R01 NS090464
Pays : United States
Organisme : NIH HHS
ID : K23NS078044
Pays : United States
Organisme : National Multiple Sclerosis Society
ID : RG 1807-31051
Pays : International
Organisme : NIH HHS
ID : R21NS106522
Pays : United States
Organisme : NIH HHS
ID : RO1 NS104283
Pays : United States
Organisme : NIH HHS
ID : 1R01NS104403-01
Pays : United States
Organisme : NIH HHS
ID : R01 NS060910
Pays : United States
Organisme : NIH HHS
ID : R01-EB007258
Pays : United States
Organisme : NIH HHS
ID : R01 NS091683
Pays : United States
Organisme : NIH HHS
ID : R01 NS085211
Pays : United States
Organisme : NIH HHS
ID : R01NS40801
Pays : United States
Organisme : NIH HHS
ID : R01 AG058773
Pays : United States
Organisme : NIH HHS
ID : R01NS109114-01
Pays : United States
Organisme : NIH HHS
ID : R01NS104149
Pays : United States
Organisme : NIH HHS
ID : R37NS041435
Pays : United States
Organisme : NINDS NIH HHS
ID : L30 NS088825
Pays : United States
Organisme : NIH HHS
ID : RO1 NS105144
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS104283
Pays : United States
Informations de copyright
© 2020 by the American Society of Neuroimaging.
Références
Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med 2018;8:a028936.
Bermel R, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5:158-70.
Oh J, Ontaneda D, Azevedo C, et al. Imaging outcome measures of neuroprotection and repair in MS: a consensus statement from NAIMS. Neurology 2019;92:519-33.
Fox R, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler 2012;18:1534-40.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology 2010;74(Suppl 3):S8-15.
Bove R, Garcha P, Bevan CJ, et al. Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditions. Neurol Neuroimmunol Neuroinflammation 2018;5:e505.
Bove R, White CC, Giovannoni G, et al. Evaluating more naturalistic outcome measures: a 1-year smartphone study in multiple sclerosis. Neurol Neuroimmunol Neuroinflammation 2015;2:e162.
Block VJ, Bove R, Zhao C, et al. Association of continuous assessment of step count by remote monitoring with disability progression among adults with multiple sclerosis. JAMA Netw Open 2019;2:e190570.
Rao SM, Losinski G, Mourany L, et al. Processing speed test: validation of a self-administered, iPad®-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler 2017;23:1929-37.
Strober LB, Rao SM, Lee J-C, et al. Cognitive impairment in multiple sclerosis: an 18 year follow-up study. Mult Scler Relat Disord 2014;3:473-81.
Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-51.
Morrow SA, O'Connor PW, Polman CH, et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 2010;16:1385-92.
Strober L, DeLuca J, Benedict RH, et al. Symbol digit modalities test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler 2019;25:1781-90.
Benedict RH, DeLuca J, Phillips G, et al. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 2017;23:721-33.
Langdon DW, Amato MP, Boringa J, et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler 2012;18:891-8.
Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-9.
McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-66.
Hoftberger R, Lassmann H. Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neuro 2017;145:263-83.
Raine C. Demyelinating disease. In: Davis R, Robertson D, eds. Textbook of Neuropathology. 3rd ed. Baltimore, MD: Williams & Wilkins; 1997:627-714.
Prineas J, McDonald W, Franklin R. Demyelinating diseases. In: Graham D, Lantos P, eds. Greenfield's Neuropathology. 7th ed. London, UK: Arnold; 2002:471-550.
Ludwin S, Raine C. The neuropathology of multiple sclerosis. In: Raine C, McFarland H, Hohlfeld R, eds. Multiple Sclerosis: A Comprehensive Text. Philadelphia, PA: Saunders Elsevier; 2008:151-7.
Moore G, Stadelmann-Nessler C. Demyelinating diseases. In: Love S, Perry A, Ironside J, Budka H, eds. Greenfield's Neuropathology. 9th ed. Boca Raton, FL: CRC Press; 2015:1297-412.
van der Valk P, Amor S. Preactive lesions in multiple sclerosis. Curr Opin Neurol 2009;22:207-13.
Kuhlmann T, Ludwin S, Prat A, et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol 2017;133:13-24.
Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-12.
Plumb J, McQuaid S, Mirakhur M, et al. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002;12:154-69.
Howell OW, Rundle JL, Garg A, et al. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J Neuropathol Exp Neurol 2010;69:1017-33.
Lucchinetti CF, Popescu BFG, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188-97.
Bø L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323-31.
Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011;134:2755-71.
Vercellino M, Masera S, Lorenzatti M, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009;68:489-502.
Haider L, Simeonidou C, Steinberger G, et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry 2014;85:1386-95.
Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123:2321-37.
Cosenza-Nashat M, Zhao ML, Suh HS, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009;35:306-28.
Politis M, Giannetti P, Su P, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 2012;79:523-30.
Rissanen E, Tuisku J, Rokka J, et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195. J Nucl Med 2014;55:939-44.
Giannetti P, Politis M, Su P, et al. Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis 2014;65:203-10.
Kaunzner UW, Kang Y, Monohan E, et al. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. Mult Scler Relat Disord 2017;15:27-33.
Sucksdorff M, Rissanen E, Tuisku J, et al. Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. J Nucl Med 2017;58:1646-51.
Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol 2012;259:1199-205.
Rissanen E, Tuisku J, Vahlberg T, et al. Microglial activation, white matter tract damage, and disability in MS. Neurol Neuroimmunol Neuroinflammation 2018;5:e443.
Hagens MHJ, Golla SV, Wijburg MT, et al. In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. J Neuroinflammation 2018;15:314-23.
Endres CJ, Pomper MG, James M, et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009;50:1276-82.
Park E, Gallezot J-D, Delgadillo A, et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging 2015;42:1081-92.
Singhal T, OʼConnor K, Dubey S, et al. 18F-PBR06 Versus 11C-PBR28 PET for assessing white matter translocator protein binding in multiple sclerosis. Clin Nucl Med 2018;43:e289-95.
Unterrainer M, Mahler C, Vomacka L, et al. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. Eur J Nucl Med Mol Imaging 2018;45:1423-31.
Ikawa M, Lohith TG, Shrestha S, et al. 11C-ER176, a Radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain. J Nucl Med 2017;58:320-5.
Beaino W, Janssen B, Kooij G, et al. Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis. J Neuroinflammation 2017;14:259.
Horti AG, Naik R, Foss CA, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci USA 2019;116:1686-91.
Hametner S, Wimmer I, Haider L, et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848-61.
Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol 2017;133:25-42.
Popescu BF, Frischer JM, Webb SM, et al. Pathogenic implications of distinct patterns of iron and zinc in chronic MS lesions. Acta Neuropathol 2017;134:45-64.
Langkammer C, Krebs N, Goessler W, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010;257:455-62.
Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707-13.
Bagnato F, Hametner S, Welch EB. Visualizing iron in multiple sclerosis. Magn Reson Imaging 2013;31:376-84.
Yao B, Ikonomidou VN, Cantor FK, et al. Heterogeneity of multiple sclerosis white matter lesions detected with T2*-weighted imaging at 7.0 tesla. J Neuroimaging 2015;25:799-806.
Absinta M, Sati P, Schindler M, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest 2016;126:2597-609.
Mehta V, Pei W, Yang G, et al. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS ONE 2013;8:e57573.
Chen W, Gauthier S, Gupta A, et al. Dynamic magnetic property of multiple sclerosis lesions at various ages measured by quantitative susceptibility mapping. Proc Intl Soc Mag Reson Med 2012;59:0692.
Wang Y, Liu T. Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker. Magn Reson Med 2015;73:82-101.
Kaunzner UW, Kang Y, Zhang S, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain 2019;142:133-45.
Yao Y, Nguyen TD, Pandya S, et al. Combining quantitative susceptibility mapping with automatic zero reference (QSM0) and myelin water fraction imaging to quantify iron-related myelin damage in chronic active MS lesions. AJNR Am J Neuroradiol 2018;39:303-10.
Absinta M, Sati P, Reich D. Advanced MRI and staging of multiple sclerosis lesions. Nat Rev Neurol 2016;12:358-68.
Absinta M, Sati P, Masuzzo F, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA neurology 2019;76:1474-83.
Abbott NJ, Patabendige AAK, Dolman DEM, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37:13-25.
Kirk J, Plumb J, Mirakhur M, et al. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003;201:319-27.
Njus JM, Li X, Springer CS, et al. DCE-MRI Ktrans mapping of MS lesion evolution in individuals. Proc Int Soc Magn Reson Med 2008;16:3434.
Goodkin DE, Rooney WD, Sloan R, et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998;51:1689-97.
Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: Pathogenetic and clinical implications. Brain 1990;113:1477-9.
Preston E, Foster DO. Evidence for pore-like opening of the blood-brain barrier following forebrain ischemia in rats. Brain Res 1997;761:4-10.
Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
Gaitán MI, Shea CD, Evangelou IE, et al. Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011;70:22-9.
Gaitán MI, Sati P, Inati SJ, et al. Initial investigation of the blood-brain barrier in MS lesions at 7 tesla. Mult Scler 2013;19:1068-73.
Yankeelov TE, Rooney WD, Huang W, et al. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 2005;18:173-85.
Rooney WD, Li X, Sammi MK, et al. Mapping human brain capillary water lifetime: high-resolution metabolic neuroimaging. NMR Biomed 2015;28:607-23.
Wengler K, Bangiyev L, Canli T, et al. 3D MRI of whole-brain water permeability with intrinsic diffusivity encoding of arterial labeled spin (IDEALS). Neuroimage 2019;189:401-14.
Shao X, Ma SJ, Casey M, et al. Mapping water exchange across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI. Magn Reson Med 2019;81:3065-79.
Lin Z, Li Y, Su P, et al. Non-contrast MR imaging of blood-brain barrier permeability to water. Magn Reson Med 2018;80:1507-20.
Mamourian AC, Hoopes PJ, Lewis LD. Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: an in vitro and animal-model investigation. AJNR Am J Neuroradiol 2000;21:105-11.
Eisele P, Griebe M, Szabo K, et al. Investigation of leptomeningeal enhancement in MS: a postcontrast FLAIR MRI study. Neurology 2015;84:770-5.
Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015;85:18-28.
Zivadinov R, Ramasamy DP, Vaneckova M, et al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: a retrospective, pilot, observational longitudinal study. Mult Scler 2017;23:1336-45.
Makshakov G, Magonov E, Totolyan N, et al. Leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple sclerosis. Neurol Res Int 2017;2017:1-7.
Zurawski J, Tauhid S, Chu R, et al. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler 2020;26:177-87.
Harrison DM, Wang KY, Fiol J, et al. Leptomeningeal enhancement at 7T in multiple sclerosis: frequency, morphology, and relationship to cortical volume. J Neuroimaging 2017;27:461-8.
Jonas SN, Izbudak I, Frazier AA, et al. Longitudinal persistence of meningeal enhancement on postcontrast 7T 3D-FLAIR MRI in multiple sclerosis. Am J Neuroradiol 2018;39:1799-805.
Ighani M, Jonas S, Izbudak I, et al. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis. Mult Scler J 2020;26:165-76.
Bhargava P, Wicken C, Smith MD, et al. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. Mult Scler Relat Disord 2019;30:136-40.
Tallantyre EC, Bø L, Al-Rawashdeh O, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 2010;16:406-11.
Compston A, Lassmann H, McDonald I. The Story of Multiple Sclerosis. In: Compston A, Confavreux C, Lassmann H, et al., eds. McAlpine's Multiple Sclerosis. Philadelphia, PA: Churchill Livingstone Elsevier; 2005:3-68.
Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain J Neurol 1997;120:393-9.
Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.
Lu J-Q, Fan Y, Mitha AP, et al. Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions. J Neuropathol Exp Neurol 2009;68:179-89.
McQuaid S, Cunnea P, McMahon J, et al. The effects of blood-brain barrier disruption on glial cell function in multiple sclerosis. Biochem Soc Trans 2009;37:329-31.
Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-80.
Christensen PC, Samadi-Bahrami Z, Pavlov V, et al. Ionotropic glutamate receptor expression in human white matter. Neurosci Lett 2016;630:1-8.
Prineas JW, Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology 1978;28:S68-75.
Craner MJ, Newcombe J, Black JA, et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci USA 2004;101:8168-73.
Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999;354:1649-73.
Kornek B, Storch MK, Bauer J, et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2001;124:1114-24.
Young EA, Fowler CD, Kidd GJ, et al. Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008;63:428-35.
Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009;132:1161-74.
Evangelou N, Esiri MM, Smith S, et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000;47:391-5.
Evangelou N, Konz D, Esiri MM, et al. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000;123:1845-9.
Singh S, Metz I, Amor S, et al. Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol 2013;125:595-608.
Zhao GJ, Li DKB, Cheng Y, et al. MRI dirty-appearing white matter in MS. (Abstract). Neurology 2000;54(Suppl 3):A121.
Laule C, Pavlova V, Leung E, et al. Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration. J Neuropathol Exp Neurol 2013;72:42-52.
Peterson JW, Bö L, Mörk S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
Klaver R, Popescu V, Voorn P, et al. Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. J Neuropathol Exp Neurol 2015;74:453-8.
Stys PK, Zamponi GW, van Minnen J, et al. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012;13:507-14.
Duarte JMN, Lei H, Mlynárik V, et al. The neurochemical profile quantified by in vivo 1H NMR spectroscopy. Neuroimage 2012;61:342-62.
Oz G, Alger JR, Barker PB, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 2014;270:658-79.
Cawley N, Ciccarelli O. MR Spectroscopy in Multiple Sclerosis. In: Öz G, ed. Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. Cham, Switzerland: Springer International Publishing; 2016:151-78.
Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128:1016-25.
Baranzini SE, Srinivasan R, Khankhanian P, et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 2010;133:2603-11.
Klauser AM, Wiebenga OT, Eijlers AJ, et al. Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis. Mult Scler 2018;24:491-500.
MacMillan E, Tam R, Zhao Y, et al. Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years. Mult Scler J 2016;22:112-6.
Muhlert N, Atzori M, De Vita E, et al. Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. J Neurol Neurosurg Psychiatry 2014;85:833-9.
Cawley N, Solanky BS, Muhlert N, et al. Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain 2015;138:2584-95.
Bhattacharyya PK, Phillips MD, Stone LA, et al. Sensorimotor cortex gamma-aminobutyric acid concentration correlates with impaired performance in patients with MS. Am J Neuroradiol 2013;34:1733-9.
Gao F, Yin X, Edden RAE, et al. Altered hippocampal GABA and glutamate levels and uncoupling from functional connectivity in multiple sclerosis. Hippocampus 2018;28:813-23.
Cao G, Edden RAE, Gao F, et al. Reduced GABA levels correlate with cognitive impairment in patients with relapsing-remitting multiple sclerosis. Eur Radiol 2018;28:1140-8.
Deelchand DK, Kantarci K, Öz G. Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting. Magn Reson Med 2018;79:1241-50.
Tkác I, Oz G, Adriany G, et al. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 2009;62:868-79.
Terpstra M, Cheong I, Lyu T, et al. Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T. Magn Reson Med 2016;76:1083-91.
Prinsen H, de Graaf RA, Mason GF, et al. Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T. J Magn Reson Imaging JMRI 2017;45:187-98.
van Munster CEP, Jonkman LE, Weinstein HC, et al. Gray matter damage in multiple sclerosis: impact on clinical symptoms. Neuroscience 2015;303:446-61.
Vinters H, Kleinschmidt-DeMasters B. General pathology of the central nervous system. In: Love S, Perry A, Ironside J, et al., eds. Greenfield's Neuropathology. 9th ed. Boca Raton, FL: CRC Press; 2015:1-58.
Gray E, Thomas TL, Betmouni S, et al. Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques. J Neuropathol Exp Neurol 2008;67:888-99.
Haider L, Zrzavy T, Hametner S, et al. The topography of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 2016;139:807-15.
Papadopoulos D, Dukes S, Patel R, et al. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol 2009;19:238-53.
Vercellino M, Plano F, Votta B, et al. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005;64:1101-7.
Wegner C, Esiri MM, Chance SA, et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006;67:960-7.
Magliozzi R, Howell OW, Reeves C, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010;68:477-93.
Gray E, Rice C, Nightingale H, et al. Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis. Mult Scler 2013;19:153-61.
Dutta R, McDonough J, Chang A, et al. Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients. Brain 2007;130:2566-76.
Schirmer L, Merkler D, König FB, et al. Neuroaxonal regeneration is more pronounced in early multiple sclerosis than in traumatic brain injury lesions. Brain Pathol 2013;23:2-12.
Evangelou N, Konz D, Esiri MM, et al. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001;124:1813-20.
Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650-3.
Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 2007;8:700-11.
Tahedl M, Levine SM, Greenlee MW, et al. Functional connectivity in multiple sclerosis: recent findings and future directions. Front Neurol 2018;9:828-46.
Roosendaal SD, Schoonheim MM, Hulst HE, et al. Resting state networks change in clinically isolated syndrome. Brain 2010;133:1612-21.
Patel KR, Tobyne S, Porter D, et al. Structural disconnection is responsible for increased functional connectivity in multiple sclerosis. Brain Struct Funct 2018;223:2519-26.
Rocca MA, Valsasina P, Leavitt VM, et al. Functional network connectivity abnormalities in multiple sclerosis: correlations with disability and cognitive impairment. Mult Scler 2018;24:459-71.
Faivre A, Robinet E, Guye M, et al. Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: a longitudinal resting-state fMRI study. Mult Scler 2016;22:1695-708.
Tavazzi E, Bergsland N, Cattaneo D, et al. Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study. J Neurol 2018;265:1393-401.
Schwartz DL, Tagge I, Powers K, et al. Multisite reliability and repeatability of an advanced brain MRI protocol. J Magn Reson Imaging JMRI 2019;50:878-88.
Birn RM, Molloy EK, Patriat R, et al. The effect of scan length on the reliability of resting-state fMRI connectivity estimates. Neuroimage 2013;83:550-8.
Braga RM, Dijk KRAV, Polimeni JR, et al. Parallel distributed networks resolved at high resolution reveal close juxtaposition of distinct regions. bioRxiv 2018:475806.
De Giglio L, Tona F, De Luca F, et al. Multiple Sclerosis: changes in thalamic resting-state functional connectivity induced by a home-based cognitive rehabilitation program. Radiology 2016;280:202-11.
Calhoun ME, Jucker M, Martin LJ, et al. Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol 1996;25:821-8.
Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661-81.
James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 2012;92:897-965.
Bajjalieh SM, Frantz GD, Weimann JM, et al. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 1994;14:5223-35.
Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-6.
Mercier J, Archen L, Bollu V, et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. Chem Med Chem 2014;9:693-8.
Cai Z, Li S, Matuskey D, et al. PET imaging of synaptic density: a new tool for investigation of neuropsychiatric diseases. Neurosci Lett 2019;691:44-50.
Nabulsi NB, Mercier J, Holden D, et al. Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. J Nucl Med 2016;57:777-84.
Finnema SJ, Nabulsi NB, Eid T, et al. Imaging synaptic density in the living human brain. Sci Transl Med 2016;8:348-96.
Warnock GI, Aerts J, Bahri MA, et al. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. J Nucl Med 2014;55:1336-41.
Cai H, Mangner TJ, Muzik O, et al. Radiosynthesis of (11)C-levetiracetam: a potential marker for PET imaging of SV2A expression. ACS Med Chem Lett 2014;5:1152-5.
Estrada S, Lubberink M, Thibblin A, et al. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A. Nucl Med Biol 2016;43:325-32.
Li S, Cai Z, Wu X, et al. Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates. ACS Chem Neurosci 2019;10:1544-54.
Cai Z, Li S, Finnema S, et al. Imaging synaptic density with novel 18F-labeled radioligands for synaptic vesicle protein-2A (SV2A): synthesis and evaluation in nonhuman primates. J Nucl Med 2017;58:547.
Kaufman AC, Salazar SV, Haas LT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol 2015;77:953-71.
Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978;4:151-62.
Gilmore CP, Bö L, Owens T, et al. Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol Zurich Switz 2006;16:202-8.
Vogt J, Paul F, Aktas O, et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol 2009;66:310-22.
Schirmer L, Albert M, Buss A, et al. Substantial early, but non-progressive neuronal loss in multiple sclerosis (MS) spinal cord. Ann Neurol 2009;66:698-704.
Bergers E, Bot JCJ, van der Valk P, et al. Diffuse signal abnormalities in the spinal cord in multiple sclerosis: direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology. Ann Neurol 2002;51:652-6.
Bergers E, Bot JCJ, De Groot CJA, et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 2002;59:1766-71.
Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 1999;25:459-67.
DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004;127:1009-18.
De Leener B, Lévy S, Dupont SM, et al. SCT: spinal cord toolbox, an open-source software for processing spinal cord MRI data. Neuroimage 2017;145:24-43.
Yiannakas MC, Mustafa AM, De Leener B, et al. Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: application to multiple sclerosis. Neuroimage Clin 2016;10:71-7.
Eden D, Gros C, Badji A, et al. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. Brain 2019;142:633-46.
Gros C, De Leener B, Badji A, et al. Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. Neuroimage 2019;184:901-15.
Dula AN, Pawate S, Dortch RD, et al. Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis at 7T. Mult Scler 2016;22:320-8.
Casserly C, Seyman EE, Alcaide-Leon P, et al. Spinal cord atrophy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimaging 2018;28:556-86.
By S, Smith AK, Dethrage LM, et al. Quantifying the impact of underlying measurement error on cervical spinal cord diffusion tensor imaging at 3T. J Magn Reson Imaging JMRI 2016;44:1608-18.
By S, Xu J, Box BA, et al. Application and evaluation of NODDI in the cervical spinal cord of multiple sclerosis patients. Neuroimage Clin 2017;15:333-42.
Grussu F, Schneider T, Zhang H, et al. Neurite orientation dispersion and density imaging of the healthy cervical spinal cord in vivo. Neuroimage 2015;111:590-601.
By S, Xu J, Box BA, et al. Multi-compartmental diffusion characterization of the human cervical spinal cord in vivo using the spherical mean technique. NMR Biomed 2018;31:e3894-4015.
Smith AK, By S, Lyttle BD, et al. Evaluating single-point quantitative magnetization transfer in the cervical spinal cord: application to multiple sclerosis. Neuroimage Clin 2017;16:58-65.
Ljungberg E, Vavasour I, Tam R, et al. Rapid myelin water imaging in human cervical spinal cord. Magn Reson Med 2017;78:1482-7.
Laule C, Vavasour IM, Zhao Y, et al. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. Mult Scler 2010;16:670-7.
van Zijl PCM, Yadav NN. Chemical exchange saturation transfer (CEST): what is in a name and what isn't? Magn Reson Med 2011;65:927-48.
By S, Barry RL, Smith AK, et al. Amide proton transfer CEST of the cervical spinal cord in multiple sclerosis patients at 3T. Magn Reson Med 2018;79:806-14.
Stroman PW, Wheeler-Kingshott C, Bacon M, et al. The current state-of-the-art of spinal cord imaging: methods. Neuroimage 2014;84:1070-81.
Barry RL, Smith SA, Dula AN, et al. Resting state functional connectivity in the human spinal cord. eLife 2014;3:e02812.
Eippert F, Kong Y, Winkler AM, et al. Investigating resting-state functional connectivity in the cervical spinal cord at 3T. Neuroimage 2017;147:589-601.
Eippert F, Tracey I. The spinal cord is never at rest. eLife 2014;3:e03811.
Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260-4
Perone CS, Calabrese E, Cohen-Adad J. Spinal cord gray matter segmentation using deep dilated convolutions. Sci Rep 2018;8:5966-79.